Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 196

1.

Assessment of acute kidney injury in neurologically and traumatically injured intensive care patients receiving large vancomycin doses.

May CC, Erwin BL, Childress M, Cortopassi J, Curtis G, Kilpatrick T, Taylor J, Vance B, Wylie D.

Int J Crit Illn Inj Sci. 2018 Oct-Dec;8(4):194-200. doi: 10.4103/IJCIIS.IJCIIS_39_18.

2.

The TAM receptor TYRO3 is a critical regulator of myelin thickness in the central nervous system.

Blades F, Aprico A, Akkermann R, Ellis S, Binder MD, Kilpatrick TJ.

Glia. 2018 Oct;66(10):2209-2220. doi: 10.1002/glia.23481. Epub 2018 Sep 12.

PMID:
30208252
3.

Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.

Stein MS, Ward GJ, Butzkueven H, Kilpatrick TJ, Harrison LC.

Mol Med. 2018 May 30;24(1):27. doi: 10.1186/s10020-018-0028-3.

4.

Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.

Jia X, Madireddy L, Caillier S, Santaniello A, Esposito F, Comi G, Stuve O, Zhou Y, Taylor B, Kilpatrick T, Martinelli-Boneschi F, Cree BAC, Oksenberg JR, Hauser SL, Baranzini SE.

Ann Neurol. 2018 Jul;84(1):51-63. doi: 10.1002/ana.25263. Epub 2018 Jul 3.

5.

MonoMac syndrome with associated neurological deficits and longitudinally extensive cord lesion.

Monif M, Huq A, Chee L, Kilpatrick T.

BMJ Case Rep. 2018 Apr 21;2018. pii: bcr-2017-222872. doi: 10.1136/bcr-2017-222872.

PMID:
29680795
6.

Fibre-specific white matter changes in multiple sclerosis patients with optic neuritis.

Gajamange S, Raffelt D, Dhollander T, Lui E, van der Walt A, Kilpatrick T, Fielding J, Connelly A, Kolbe S.

Neuroimage Clin. 2017 Sep 29;17:60-68. doi: 10.1016/j.nicl.2017.09.027. eCollection 2018.

7.

Technologies for Advanced Gait and Balance Assessments in People with Multiple Sclerosis.

Shanahan CJ, Boonstra FMC, Cofré Lizama LE, Strik M, Moffat BA, Khan F, Kilpatrick TJ, van der Walt A, Galea MP, Kolbe SC.

Front Neurol. 2018 Feb 2;8:708. doi: 10.3389/fneur.2017.00708. eCollection 2017. Review.

8.

Pharmacogenetic stimulation of neuronal activity increases myelination in an axon-specific manner.

Mitew S, Gobius I, Fenlon LR, McDougall SJ, Hawkes D, Xing YL, Bujalka H, Gundlach AL, Richards LJ, Kilpatrick TJ, Merson TD, Emery B.

Nat Commun. 2018 Jan 22;9(1):306. doi: 10.1038/s41467-017-02719-2.

9.

Achievements and obstacles of remyelinating therapies in multiple sclerosis.

Stangel M, Kuhlmann T, Matthews PM, Kilpatrick TJ.

Nat Rev Neurol. 2017 Dec;13(12):742-754. doi: 10.1038/nrneurol.2017.139. Epub 2017 Nov 17. Review.

10.

A Brain-Derived Neurotrophic Factor-Based p75NTR Peptide Mimetic Ameliorates Experimental Autoimmune Neuritis Induced Axonal Pathology and Demyelination.

Gonsalvez DG, Tran G, Fletcher JL, Hughes RA, Hodgkinson S, Wood RJ, Yoo SW, De Silva M, Agnes WW, McLean C, Kennedy P, Kilpatrick TJ, Murray SS, Xiao J.

eNeuro. 2017 Jul 4;4(3). pii: ENEURO.0142-17.2017. doi: 10.1523/ENEURO.0142-17.2017. eCollection 2017 May-Jun.

11.

Multiple Sclerosis: Basic and Clinical.

Buzzard K, Chan WH, Kilpatrick T, Murray S.

Adv Neurobiol. 2017;15:211-252. doi: 10.1007/978-3-319-57193-5_8. Review.

PMID:
28674983
12.

Gait and balance deterioration over a 12-month period in multiple sclerosis patients with EDSS scores ≤ 3.0.

Galea MP, Cofré Lizama LE, Butzkueven H, Kilpatrick TJ.

NeuroRehabilitation. 2017;40(2):277-284. doi: 10.3233/NRE-161413.

PMID:
28222549
13.

The TAM receptor Tyro3 regulates myelination in the central nervous system.

Akkermann R, Aprico A, Perera AA, Bujalka H, Cole AE, Xiao J, Field J, Kilpatrick TJ, Binder MD.

Glia. 2017 Apr;65(4):581-591. doi: 10.1002/glia.23113. Epub 2017 Feb 1.

PMID:
28145605
14.

A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180-190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.

Gonsalvez DG, De Silva M, Wood RJ, Giuffrida L, Kilpatrick TJ, Murray SS, Xiao J.

J Neuropathol Exp Neurol. 2017 Feb 1;76(2):89-100. doi: 10.1093/jnen/nlw110.

PMID:
28082327
15.

Interleukin-2 receptor-α proximal promoter hypomethylation is associated with multiple sclerosis.

Field J, Fox A, Jordan MA, Baxter AG, Spelman T, Gresle M, Butzkueven H, Kilpatrick TJ, Rubio JP.

Genes Immun. 2017 Mar;18(2):59-66. doi: 10.1038/gene.2016.50. Epub 2017 Jan 12.

PMID:
28077880
17.

Stressful life events and the risk of initial central nervous system demyelination.

Saul A, Ponsonby AL, Lucas RM, Taylor BV, Simpson S Jr, Valery P, Dwyer T, Kilpatrick TJ, Pender MP, van der Mei IA.

Mult Scler. 2017 Jun;23(7):1000-1007. doi: 10.1177/1352458516667566. Epub 2016 Sep 6.

PMID:
27600112
18.

Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis.

Kolbe SC, van der Walt A, Butzkueven H, Klistorner A, Egan GF, Kilpatrick TJ.

J Ophthalmol. 2016;2016:2764538. doi: 10.1155/2016/2764538. Epub 2016 Jul 31.

19.

Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve.

Gresle MM, Liu Y, Kilpatrick TJ, Kemper D, Wu QZ, Hu B, Fu QL, So KF, Sheng G, Huang G, Pepinsky B, Butzkueven H, Mi S.

Mult Scler J Exp Transl Clin. 2016 Apr 19;2:2055217316641704. doi: 10.1177/2055217316641704. eCollection 2016 Jan-Dec.

20.

Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status.

Binder MD, Fox AD, Merlo D, Johnson LJ, Giuffrida L, Calvert SE, Akkermann R, Ma GZ; ANZgene, Perera AA, Gresle MM, Laverick L, Foo G, Fabis-Pedrini MJ, Spelman T, Jordan MA, Baxter AG, Foote S, Butzkueven H, Kilpatrick TJ, Field J.

PLoS Genet. 2016 Mar 18;12(3):e1005853. doi: 10.1371/journal.pgen.1005853. eCollection 2016 Mar.

21.

Fyn is an intermediate kinase that BDNF utilizes to promote oligodendrocyte myelination.

Peckham H, Giuffrida L, Wood R, Gonsalvez D, Ferner A, Kilpatrick TJ, Murray SS, Xiao J.

Glia. 2016 Feb;64(2):255-69. doi: 10.1002/glia.22927. Epub 2015 Oct 9.

PMID:
26449489
22.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
23.

Association of plasma levels of Protein S with disease severity in multiple sclerosis.

Ma GZ, Giuffrida LL, Gresle MM, Haartsen J, Laverick L, Butzkueven H, Field J, Binder MD, Kilpatrick TJ.

Mult Scler J Exp Transl Clin. 2015 Jul 24;1:2055217315596532. doi: 10.1177/2055217315596532. eCollection 2015 Jan-Dec.

24.

Population attributable fractions and joint effects of key risk factors for multiple sclerosis.

van der Mei I, Lucas RM, Taylor BV, Valery PC, Dwyer T, Kilpatrick TJ, Pender MP, Williams D, Chapman C, Otahal P, Ponsonby AL.

Mult Scler. 2016 Apr;22(4):461-9. doi: 10.1177/1352458515594040. Epub 2015 Jul 21.

PMID:
26199349
25.

A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis.

Gu BJ, Field J, Dutertre S, Ou A, Kilpatrick TJ, Lechner-Scott J, Scott R, Lea R, Taylor BV, Stankovich J, Butzkueven H, Gresle M, Laws SM, Petrou S, Hoffjan S, Akkad DA, Graham CA, Hawkins S, Glaser A, Bedri SK, Hillert J, Matute C, Antiguedad A; ANZgene Consortium, Wiley JS.

Hum Mol Genet. 2015 Oct 1;24(19):5644-54. doi: 10.1093/hmg/ddv278. Epub 2015 Jul 17.

PMID:
26188005
26.

The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function.

Field J, Shahijanian F, Schibeci S; Australia and New Zealand MS Genetics Consortium (ANZgene), Johnson L, Gresle M, Laverick L, Parnell G, Stewart G, McKay F, Kilpatrick T, Butzkueven H, Booth D.

PLoS One. 2015 Jun 11;10(6):e0127080. doi: 10.1371/journal.pone.0127080. eCollection 2015.

27.

Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis.

van der Walt A, Kolbe S, Mitchell P, Wang Y, Butzkueven H, Egan G, Yiannikas C, Graham S, Kilpatrick T, Klistorner A.

PLoS One. 2015 May 28;10(5):e0121084. doi: 10.1371/journal.pone.0121084. eCollection 2015.

28.

Galanin is an autocrine myelin and oligodendrocyte trophic signal induced by leukemia inhibitory factor.

Gresle MM, Butzkueven H, Perreau VM, Jonas A, Xiao J, Thiem S, Holmes FE, Doherty W, Soo PY, Binder MD, Akkermann R, Jokubaitis VG, Cate HS, Marriott MP, Gundlach AL, Wynick D, Kilpatrick TJ.

Glia. 2015 Jun;63(6):1005-20. doi: 10.1002/glia.22798. Epub 2015 Jan 29.

PMID:
25639936
29.

Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation.

Jonas A, Thiem S, Kuhlmann T, Wagener R, Aszodi A, Nowell C, Hagemeier K, Laverick L, Perreau V, Jokubaitis V, Emery B, Kilpatrick T, Butzkueven H, Gresle M.

J Clin Invest. 2014 Nov;124(11):5042-56. doi: 10.1172/JCI71385. Epub 2014 Oct 20.

30.

Adult neural precursor cells from the subventricular zone contribute significantly to oligodendrocyte regeneration and remyelination.

Xing YL, Röth PT, Stratton JA, Chuang BH, Danne J, Ellis SL, Ng SW, Kilpatrick TJ, Merson TD.

J Neurosci. 2014 Oct 15;34(42):14128-46. doi: 10.1523/JNEUROSCI.3491-13.2014.

31.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1857-65. doi: 10.1016/j.jocn.2014.01.017. Epub 2014 Jun 30. Review.

PMID:
24993136
32.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1835-46. doi: 10.1016/j.jocn.2014.01.016. Epub 2014 Jun 30. Review.

PMID:
24993135
33.

Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies J, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E; MS Neurology Group of the Australian and New Zealand Association of Neurologists.

J Clin Neurosci. 2014 Nov;21(11):1847-56. doi: 10.1016/j.jocn.2014.01.018. Epub 2014 Jun 28. Review.

PMID:
24986155
34.

Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution.

Gresle MM, Schulz K, Jonas A, Perreau VM, Cipriani T, Baxter AG, Miranda-Hernandez S, Field J, Jokubaitis VG, Cherny R, Volitakis I, David S, Kilpatrick TJ, Butzkueven H.

J Neurosci Res. 2014 Jun;92(6):732-42. doi: 10.1002/jnr.23349. Epub 2014 Jan 27.

PMID:
24615902
35.

All-semiconductor negative-index plasmonic absorbers.

Law S, Roberts C, Kilpatrick T, Yu L, Ribaudo T, Shaner EA, Podolskiy V, Wasserman D.

Phys Rev Lett. 2014 Jan 10;112(1):017401. Epub 2014 Jan 6.

PMID:
24483930
36.

Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes.

van der Walt A, Kolbe SC, Wang YE, Klistorner A, Shuey N, Ahmadi G, Paine M, Marriott M, Mitchell P, Egan GF, Butzkueven H, Kilpatrick TJ.

PLoS One. 2013 Dec 26;8(12):e83825. doi: 10.1371/journal.pone.0083825. eCollection 2013.

37.

Nanodiamonds with silicon vacancy defects for nontoxic photostable fluorescent labeling of neural precursor cells.

Merson TD, Castelletto S, Aharonovich I, Turbic A, Kilpatrick TJ, Turnley AM.

Opt Lett. 2013 Oct 15;38(20):4170-3. doi: 10.1364/OL.38.004170.

PMID:
24321951
38.

Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis.

Jokubaitis VG, Gresle MM, Kemper DA, Doherty W, Perreau VM, Cipriani TL, Jonas A, Shaw G, Kuhlmann T, Kilpatrick TJ, Butzkueven H.

Acta Neuropathol Commun. 2013 Jul 9;1:32. doi: 10.1186/2051-5960-1-32.

39.

Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.

Kalincik T, Vivek V, Jokubaitis V, Lechner-Scott J, Trojano M, Izquierdo G, Lugaresi A, Grand'maison F, Hupperts R, Oreja-Guevara C, Bergamaschi R, Iuliano G, Alroughani R, Van Pesch V, Amato MP, Slee M, Verheul F, Fernandez-Bolanos R, Fiol M, Spitaleri DL, Cristiano E, Gray O, Cabrera-Gomez JA, Shaygannejad V, Herbert J, Vucic S, Needham M, Petkovska-Boskova T, Sirbu CA, Duquette P, Girard M, Grammond P, Boz C, Giuliani G, Rio ME, Barnett M, Flechter S, Moore F, Singhal B, Bacile EA, Saladino ML, Shaw C, Skromne E, Poehlau D, Vella N, Spelman T, Liew D, Kilpatrick TJ, Butzkueven H; MSBase Study Group.

Brain. 2013 Dec;136(Pt 12):3609-17. doi: 10.1093/brain/awt281. Epub 2013 Oct 18.

PMID:
24142147
40.

Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.

International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, Patsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL, Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P, di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL.

Nat Genet. 2013 Nov;45(11):1353-60. doi: 10.1038/ng.2770. Epub 2013 Sep 29.

41.

Inhibitory saccadic dysfunction is associated with cerebellar injury in multiple sclerosis.

Kolbe SC, Kilpatrick TJ, Mitchell PJ, White O, Egan GF, Fielding J.

Hum Brain Mapp. 2014 May;35(5):2310-9. doi: 10.1002/hbm.22329. Epub 2013 Sep 3.

PMID:
24038970
42.

The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: the Ausimmune study.

Ponsonby AL, Lucas RM, Dear K, van der Mei I, Taylor B, Chapman C, Coulthard A, Dwyer T, Kilpatrick TJ, McMichael AJ, Pender MP, Valery PC, Williams D.

Mult Scler. 2013 Nov;19(13):1717-25. doi: 10.1177/1352458513483887. Epub 2013 May 13.

PMID:
23670542
43.

Investigation of sequential growth factor delivery during cuprizone challenge in mice aimed to enhance oligodendrogliogenesis and myelin repair.

Sabo JK, Aumann TD, Kilpatrick TJ, Cate HS.

PLoS One. 2013 May 1;8(5):e63415. doi: 10.1371/journal.pone.0063415. Print 2013.

44.

Early-life hygiene-related factors affect risk of central nervous system demyelination and asthma differentially.

Hughes AM, Lucas RM, McMichael AJ, Dwyer T, Pender MP, van der Mei I, Taylor BV, Valery P, Chapman C, Coulthard A, Dear K, Kilpatrick TJ, Williams D, Ponsonby AL.

Clin Exp Immunol. 2013 Jun;172(3):466-74. doi: 10.1111/cei.12077.

45.

Occupational exposure and risk of central nervous system demyelination.

Valery PC, Lucas RM, Williams DB, Pender MP, Chapman C, Coulthard A, Dear K, Dwyer T, Kilpatrick TJ, McMichael AJ, van der Mei I, Taylor BV, Ponsonby AL.

Am J Epidemiol. 2013 May 1;177(9):954-61. doi: 10.1093/aje/kws361. Epub 2013 Apr 12.

PMID:
23585328
46.

Oligodendroglial expression of TrkB independently regulates myelination and progenitor cell proliferation.

Wong AW, Xiao J, Kemper D, Kilpatrick TJ, Murray SS.

J Neurosci. 2013 Mar 13;33(11):4947-57. doi: 10.1523/JNEUROSCI.3990-12.2013.

47.

Vitamin D status: multifactorial contribution of environment, genes and other factors in healthy Australian adults across a latitude gradient.

Lucas RM, Ponsonby AL, Dear K, Valery PC, Taylor B, van der Mei I, McMichael AJ, Pender MP, Chapman C, Coulthard A, Kilpatrick TJ, Stankovich J, Williams D, Dwyer T.

J Steroid Biochem Mol Biol. 2013 Jul;136:300-8. doi: 10.1016/j.jsbmb.2013.01.011. Epub 2013 Feb 8. Review.

PMID:
23395985
48.

EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE).

Munro KM, Dixon KJ, Gresle MM, Jonas A, Kemper D, Doherty W, Fabri LJ, Owczarek CM, Pearse M, Boyd AW, Kilpatrick TJ, Butzkueven H, Turnley AM.

PLoS One. 2013;8(2):e55948. doi: 10.1371/journal.pone.0055948. Epub 2013 Feb 4.

49.

A small peptide mimetic of brain-derived neurotrophic factor promotes peripheral myelination.

Xiao J, Hughes RA, Lim JY, Wong AW, Ivanusic JJ, Ferner AH, Kilpatrick TJ, Murray SS.

J Neurochem. 2013 May;125(3):386-98. doi: 10.1111/jnc.12168. Epub 2013 Feb 24.

50.

The stretcher spontaneous neurodegenerative mutation models Charcot-Marie-Tooth disease type 4D.

Chandler D, Lopaticki S, Huang D, Hunter M, Angelicheva D, Kilpatrick T, King RH, Kalaydjieva L, Morahan G.

F1000Res. 2013 Feb 13;2:46. doi: 10.12688/f1000research.2-46.v1. eCollection 2013.

Supplemental Content

Loading ...
Support Center